BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37788223)

  • 21. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
    Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
    Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model.
    Han SS; Erdogan SA; Toumazis I; Leung A; Plevritis SK
    Cancer Causes Control; 2017 Sep; 28(9):947-958. PubMed ID: 28702814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Machine Learning for Early Lung Cancer Identification Using Routine Clinical and Laboratory Data.
    Gould MK; Huang BZ; Tammemagi MC; Kinar Y; Shiff R
    Am J Respir Crit Care Med; 2021 Aug; 204(4):445-453. PubMed ID: 33823116
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessing Different Approaches to Leveraging Historical Smoking Exposure Data to Better Select Lung Cancer Screening Candidates: A Retrospective Validation Study.
    Kats DJ; Adie Y; Tlimat A; Greco PJ; Kaelber DC; Tarabichi Y
    Nicotine Tob Res; 2021 Aug; 23(8):1334-1340. PubMed ID: 32974635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial.
    Tammemägi MC; Ten Haaf K; Toumazis I; Kong CY; Han SS; Jeon J; Commins J; Riley T; Meza R
    JAMA Netw Open; 2019 Mar; 2(3):e190204. PubMed ID: 30821827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung cancer risk by years since quitting in 30+ pack year smokers.
    Pinsky PF; Zhu CS; Kramer BS
    J Med Screen; 2015 Sep; 22(3):151-7. PubMed ID: 25926339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered?
    Pinsky PF; Berg CD
    J Med Screen; 2012 Sep; 19(3):154-6. PubMed ID: 23060474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk prediction models versus simplified selection criteria to determine eligibility for lung cancer screening: an analysis of German federal-wide survey and incidence data.
    Hüsing A; Kaaks R
    Eur J Epidemiol; 2020 Oct; 35(10):899-912. PubMed ID: 32594286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Tammemägi MC; Cina K; Kitts AKB; Koop D; Petereit MA; Sargent M; Petereit DG
    Cancer; 2023 Dec; 129(24):3894-3904. PubMed ID: 37807694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 'Reduced' HUNT model outperforms NLST and NELSON study criteria in predicting lung cancer in the Danish screening trial.
    Røe OD; Markaki M; Tsamardinos I; Lagani V; Nguyen OTD; Pedersen JH; Saghir Z; Ashraf HG
    BMJ Open Respir Res; 2019; 6(1):e000512. PubMed ID: 31803478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Prediction Models for Identifying Malignancy in Pulmonary Nodules Detected via Low-Dose Computed Tomography.
    González Maldonado S; Delorme S; Hüsing A; Motsch E; Kauczor HU; Heussel CP; Kaaks R
    JAMA Netw Open; 2020 Feb; 3(2):e1921221. PubMed ID: 32058555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Barry SA; Tammemagi MC; Penek S; Kassan EC; Dorfman CS; Riley TL; Commin J; Taylor KL
    J Natl Cancer Inst; 2012 Nov; 104(21):1647-59. PubMed ID: 23104210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying high-risk individuals for lung cancer screening: Going beyond NLST criteria.
    Fu M; Travier N; Martín-Sánchez JC; Martínez-Sánchez JM; Vidal C; Garcia M;
    PLoS One; 2018; 13(4):e0195441. PubMed ID: 29621354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
    ; Guida F; Sun N; Bantis LE; Muller DC; Li P; Taguchi A; Dhillon D; Kundnani DL; Patel NJ; Yan Q; Byrnes G; Moons KGM; Tjønneland A; Panico S; Agnoli C; Vineis P; Palli D; Bueno-de-Mesquita B; Peeters PH; Agudo A; Huerta JM; Dorronsoro M; Barranco MR; Ardanaz E; Travis RC; Byrne KS; Boeing H; Steffen A; Kaaks R; Hüsing A; Trichopoulou A; Lagiou P; La Vecchia C; Severi G; Boutron-Ruault MC; Sandanger TM; Weiderpass E; Nøst TH; Tsilidis K; Riboli E; Grankvist K; Johansson M; Goodman GE; Feng Z; Brennan P; Johansson M; Hanash SM
    JAMA Oncol; 2018 Oct; 4(10):e182078. PubMed ID: 30003238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. External validation and recalibration of the Brock model to predict probability of cancer in pulmonary nodules using NLST data.
    Winter A; Aberle DR; Hsu W
    Thorax; 2019 Jun; 74(6):551-563. PubMed ID: 30898897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
    Fahrmann JF; Marsh T; Irajizad E; Patel N; Murage E; Vykoukal J; Dennison JB; Do KA; Ostrin E; Spitz MR; Lam S; Shete S; Meza R; Tammemägi MC; Feng Z; Hanash SM
    J Clin Oncol; 2022 Mar; 40(8):876-883. PubMed ID: 34995129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
    Robbins HA; Alcala K; Swerdlow AJ; Schoemaker MJ; Wareham N; Travis RC; Crosbie PAJ; Callister M; Baldwin DR; Landy R; Johansson M
    Br J Cancer; 2021 Jun; 124(12):2026-2034. PubMed ID: 33846525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
    J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The National Lung Screening Trial Premise of Null and Chest Radiography Equivalence Is Open to Question.
    Reich JM; Kim JS
    AJR Am J Roentgenol; 2015 Aug; 205(2):278-9. PubMed ID: 26204275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methods for Using Race and Ethnicity in Prediction Models for Lung Cancer Screening Eligibility.
    Landy R; Gomez I; Caverly TJ; Kawamoto K; Rivera MP; Robbins HA; Young CD; Chaturvedi AK; Cheung LC; Katki HA
    JAMA Netw Open; 2023 Sep; 6(9):e2331155. PubMed ID: 37721755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.